G
Guillaume Butler-Laporte
Researcher at McGill University
Publications - 72
Citations - 1522
Guillaume Butler-Laporte is an academic researcher from McGill University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 44 publications receiving 408 citations. Previous affiliations of Guillaume Butler-Laporte include Jewish General Hospital & McGill University Health Centre.
Papers
More filters
Journal ArticleDOI
Circulating proteins to predict COVID-19 severity.
Chen-Yang Su,Sirui Zhou,Edgar Gonzalez-Kozlova,Guillaume Butler-Laporte,Elsa Brunet-Ratnasingham,Tomoko Nakanishi,Wonseok Jeon,David R. Morrison,Lætitia Laurent,Jonathan Afilalo,Marc Afilalo,D. Henry,Yiheng Chen,Julia Carrasco-Zanini,Yossi Farjoun,Maik Pietzner,N. A. Kimchi,Zaman Afrasiabi,Nardin Rezk,M. Bouab,Louis Petitjean,Charlotte Guzman,Xiaoqing Xue,Chris Tselios,Branka Vulesevic,Olumide Adeleye,Tala Abdullah,Noor Almamlouk,Yara Moussa,Chantal DeLuca,N Duggan,Erwin Schurr,Nathalie Brassard,Madeleine Durand,Diane Marie Del Valle,Ryan F. Thompson,Mario A. Cedillo,Eric E. Schadt,Kai Nie,Nicole W. Simons,Konstantinos Mouskas,Nicolas Zaki,Manishkumar Dasharathalal Patel,Hui Xie,Jocelyn Harris,Robert Marvin,Esther Cheng,Kevin Tuballes,Kimberly Argueta,Ieisha Scott,Celia M. T. Greenwood,Clare Paterson,Michael A Hinterberg,Claudia Langenberg,Vincenzo Forgetta,J. Pineau,Vincent Mooser,Thomas U. Marron,Noam D. Beckmann,Seunghee Kim-Schulze,Alexander W. Charney,Sacha Gnjatic,Daniel Kaufmann,Miriam Merad,J. Brent Richards +64 more
TL;DR: In this paper , the authors measured 4701 circulating human protein abundances in two independent cohorts totaling 986 individuals and trained prediction models including protein abundance and clinical risk factors to predict COVID-19 severity.
Journal ArticleDOI
Handheld infrared thermometer to evaluate cellulitis: the HI-TEC study
Koray Demir,Emily G. McDonald,Samuel De l'Étoile-Morel,Lorne Schweitzer,Guillaume Butler-Laporte,Matthew P. Cheng,Todd C. Lee +6 more
TL;DR: In this article, the authors evaluated the utility of a handheld infrared thermometer to improve diagnostic certainty in cases of suspected cellulitis, using Youden's method to determine the optimal temperature difference which best differentiated cellulitis from pseudocellulitis.
Journal ArticleDOI
Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis.
Guillaume Butler-Laporte,Matthew P. Cheng,Daniel J. G. Thirion,Daniel J. G. Thirion,Samuel De l'Étoile-Morel,Charles Frenette,Katryn Paquette,Alexander Lawandi,Emily G. McDonald,Todd C. Lee +9 more
TL;DR: Despite the DASH trial being a negative study, it impacted the prescribing habits of local clinicians during recruitment, and trialists should be aware of potential off-target study effects, and prescribers should be wary of early uptake of interventions before definitive study results.
Journal ArticleDOI
2116. Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis
TL;DR: In a meta-analysis comparing treatment strategies for severe Candida infections, the echinocandins had the highest rate of treatment success compared with both amphotericin B and triazoles, and should be considered as first-line agents in the treatment of invasive candidiasis and candidemia.
Journal ArticleDOI
Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
Zahra N. Sohani,Guillaume Butler-Laporte,Andrew Aw,Sara Belga,Andrea Benedetti,Alex Carignan,Matthew P. Cheng,Bryan Coburn,Cecilia T. Costiniuk,Nicole Ezer,Daniel B. Gregson,Andrew Johnson,Kosar Khwaja,Alexander Lawandi,Victor C. M. Leung,Sylvain A. Lother,Derek R. MacFadden,Michaeline McGuinty,Leighanne O Parkes,Salman T. Qureshi,Valerie Roy,Barret Rush,Ilan S. Schwartz,Miranda So,Ranjani Somayaji,Darrell H. S. Tan,Emilie Trinh,Todd A. Lee,Emily G. McDonald +28 more
TL;DR: A phase III randomised, placebo-controlled, trial to directly compare the efficacy and safety of low-dose TMP-SMX with the standard of care among patients with PJP, for a composite primary outcome of change of treatment, new mechanical ventilation, or death.